© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Based on recent data, Aurinia Pharmaceuticals Inc. (AUPH) shows an Average True Range (ATR) of 0.47 and an Enterprise Value of 776.16M. Its average trading volume over the past 3 months is 1.43M, indicating liquidity. These fundamental metrics provide insight into AUPH's underlying financial health and market activity.
Aurinia Pharmaceuticals Inc. (AUPH) technical indicators as of December 31, 2025: the SMA 20 is 0.02%, SMA 50 at 6.47%, and SMA 200 at 45.17%. The RSI 14 value is 53.46, suggesting its current momentum. These technical analysis signals help assess AUPH's price trends and potential future movements.
Aurinia Pharmaceuticals Inc. (AUPH) stock performance overview as of December 31, 2025: The 52-week high is $16.54 (currently -4.35% below), and the 52-week low is $6.55 (currently 141.53% above). Over the past year, AUPH's performance is 76.76%, compared to the S&P 500's 11.81% change.
According to market data, Aurinia Pharmaceuticals Inc. (AUPH) stock's recent performance metrics show that over the last month, AUPH is -3.36%, with a Year-to-Date (YTD) performance of 76.17%. Over the past year, the stock has seen a 76.76% change. These figures summarize AUPH's price movements across various periods, reflecting its historical returns.
According to current financial data, AUPH stock's P/E (TTM) ratio is 28.64, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.24. Key valuation ratios for AUPH, including P/S (8.06), P/B (6.09), and P/FCF (17.87), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.